Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
4D Molecular Therapeutics develops gene therapy medicines designed to treat eye, lung, and heart diseases.
4D Molecular Therapeutics is a gene therapy company. It builds medicines that deliver a working copy of a gene into a patient's cells, so the body can make a missing or broken protein itself. The company focuses on three areas: eye diseases, lung diseases, and heart diseases.
The core technology is a library of engineered viruses, called vectors, that act as delivery trucks. A virus is naturally good at getting inside cells, so scientists strip out the parts that cause disease and load in a therapeutic gene instead. 4D's twist is that it designs these vectors from scratch and tests huge numbers of them to find ones that reach a specific tissue — say, the retina or the lung — when injected in a simple way. That matters because older gene therapies often required surgery or risky high doses. If a vector can be given as an ordinary injection and still reach the right cells, treatment becomes safer and easier. Its lead programs target wet age-related macular degeneration and diabetic macular edema, two common causes of vision loss, using a vector injected into the eye. It is also developing inhaled treatments for lung diseases such as cystic fibrosis and a heart treatment for a genetic condition that causes heart failure. The company earns no product revenue yet; it funds itself through stock sales, partnerships, and licensing deals while its candidates move through clinical trials. That is the central risk and the central bet: gene therapy is expensive to develop, trials can fail, and regulators must be convinced the treatments are safe.
The field is crowded and volatile. Competitors include Spark Therapeutics-style gene therapy pioneers and larger players such as Novartis and Regeneron, which already sell eye drugs that 4D hopes to replace with one-time treatments. Success depends on clinical data and on manufacturing enough vector reliably. Investors are essentially paying for a pipeline of experiments, so the stock swings hard on trial results.
Saved answer · last researched 16 Nov 2026